Long-term safety, tolerability, and efficacy of Efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from the ADAPT plus study

被引：1

作者：

Ashcraft, E. ^{[1
]}

Bril, V. ^{[2
,3
]}

Pasnoor, M. ^{[4
]}

Karam, C. ^{[5
]}

Peric, S. ^{[6
]}

De Bleecker, J. ^{[7
]}

Murai, H. ^{[8
]}

Meisel, A. ^{[9
,10
]}

Beydoun, S. ^{[11
]}

Vu, T. ^{[12
]}

Ulrichts, P. ^{[1
]}

Van Hoorick, B. ^{[1
]}

T'joen, C. ^{[1
]}

Utsugisawa, K. ^{[13
]}

Verschuuren, J. ^{[14
]}

Mantegazza, R. ^{[15
]}

Howard, J. ^{[16
]}

机构：

[1] Argenx, Ghent, Belgium

[2] Univ Hlth Network, Ellen & Martin Prosserman Ctr Neuromuscular Dis, Toronto, ON, Canada

[3] Univ Toronto, Toronto, ON, Canada

[4] Univ Kansas, Dept Neurol, Med Ctr, Kansas City, MO USA

[5] Univ Penn, Penn Neurosci Ctr Hosp, Philadelphia, PA USA

[6] Univ Belgrade, Clin Ctr Serbia, Neurol Clin, Belgrade, Serbia

[7] Ghent Univ Hosp, Ghent, Belgium

[8] Int Univ Hlth & Welf, Sch Med, Dept Neurol, Tokyo, Japan

[9] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany

[10] Charite Univ Med Berlin, NeuroCure Clin Res Ctr, Berlin, Germany

[11] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA

[12] Univ S Florida, Dept Neurol, Morsani Coll Med, Tampa, FL USA

[13] Hanamaki Gen Hosp, Dept Neurol, Hanamaki, Japan

[14] Leiden Univ, Dept Neurol, Med Ctr, Leiden, Netherlands

[15] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neuroimmunol & Neuromuscular Dis, Milan, Italy

[16] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA

来源：

NEUROMUSCULAR DISORDERS | 2023年 / 33卷

关键词：

D O I：

10.1016/j.nmd.2023.07.444

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P277

引用

页码：S179 / S179

页数：1

共 50 条

[1] Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized myasthenia gravis: Concluding analyses from the ADAPT plus study
Bril, Vera
Pasnoor, Mamatha
Karam, Chafic
Peric, Stojan
De Bleecker, Jan L.
Murai, Hiroyuki
Meisel, Andreas
Beydoun, Said
Vu, Tuan
Ulrichts, Peter
Van Hoorick, Benjamin
T'Joen, Caroline
Kaprielian, Roger
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
Howard, James F., Jr.
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
[2] Long-Term Safety, Tolerability, And Efficacy of Efgartigimod in Patients with Generalized Myasthenia Gravis: Concluding Analyses from the ADAPT plus Study
Pasnoor, Mamatha
Bril, Vera
Karam, Chafic
Peric, Stojan
De Bleecker, Jan
Murai, Hiroyuki
Meisel, Andreas
Beydoun, Said
Vu, Tuan
Ulrichts, Peter
Van Hoorick, Benjamin
T'joen, Caroline
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
Howard, James
[J]. NEUROLOGY, 2023, 100 (17)
[3] LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT plus STUDY
Howard, James F., Jr.
Bril, Vera
Tuan Vu
Karam, Chafic
Peric, Stojan
De Bleecker, Jan L.
Murai, Hiroyuki
Meisel, Andreas
Beydoun, Said
Pasnoor, Mamatha
Guglietta, Antonio
T'joen, Caroline
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
[J]. MUSCLE & NERVE, 2022, 65 : S9 - S10
[4] LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT plus STUDY
Howard, James
Bril, Vera
Tuan Vu
Karam, Chafic
Peric, Stojan
De Bleecker, Jan
Murai, Hiroyuki
Meisel, Andreas
Beydoun, Said
Pasnoor, Mamatha
Guglietta, Antonio
T'joen, Caroline
Utsugisawa, Kimiaki
Mantegazza, Renato
[J]. MUSCLE & NERVE, 2022, 66 : S57 - S57
[5] Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT plus Study
Howard, James
Bril, Vera
Vu, Tuan
Karam, Chafic
Peric, Stojan
De Bleecker, Jan
Murai, Hiroyuki
Meisel, Andreas
Beydoun, Said
Pasnoor, Mamatha
Guglietta, Antonio
Ulrichts, Peter
T'joen, Caroline
Brauer, Edward
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
[J]. NEUROLOGY, 2022, 99 (23) : S37 - S38
[6] Long-Term Safety, Tolerability, And Efficacy of Efgartigimod In Patients With gMG: Final Analyses From The ADAPT plus Study
Meisel, A.
De Bleecker, J.
Verschuuren, J.
Bril, V.
Vu, T.
Karam, C.
Peric, S.
Murai, H.
Beydoun, S.
Pasnoor, M.
Steeland, S.
Van Hoorick, B.
T'joen, C.
Utsugisawa, K.
Mantegazza, R.
Howard, J.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 208 - 209
[7] Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC plus Study
Howard, James
Li, George
Vu, Tuan
Korobko, Denis
Smilowski, Marek
Liu, Li
Steeland, Sophie
Noukens, Jan
Van Hoorick, Benjamin
Podhorna, Jana
Li, Yuebing
Utsugisawa, Kimiaki
Sacca, Francesco
Wiendl, Heinz
De Bleecker, Jan
Mantegazza, Renato
[J]. NEUROLOGY, 2023, 100 (17)
[8] Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study
Howard, James
Bril, Vera
Vu, Tuan
Karam, Chafic
Peric, Stojan
Murai, Hiroyuki
Guglietta, Antonio
Ulrichts, Peter
Vangeneugden, Tony
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
[J]. NEUROLOGY, 2021, 96 (15)
[9] Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC plus Study
Ritt, Elissa
Howard, James F., Jr.
Li, George
Vu, Tuan
Korobko, Denis
Smilowski, Marek
Liu, Li
Steeland, Sophie
Noukens, Jan
Van Hoorick, Benjamin
Podhorna, Jana
Li, Yuebing
Utsugisawa, Kimiaki
Sacca, Francesco
Wiendl, Heinz
De Bleecker, Jan L.
Mantegazza, Renato
[J]. ANNALS OF NEUROLOGY, 2023, 94 : S244 - S245
[10] Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT plus ): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
Howard Jr, James F.
Bril, Vera
Vu, Tuan
Karam, Chafic
Peric, Stojan
De Bleecker, Jan L.
Murai, Hiroyuki
Meisel, Andreas
Beydoun, Said R.
Pasnoor, Mamatha
Guglietta, Antonio
Van Hoorick, Benjamin
Steeland, Sophie
T'joen, Caroline
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
[J]. FRONTIERS IN NEUROLOGY, 2024, 14

← 1 2 3 4 5 →